Truist raised the firm’s price target on iRhythm (IRTC) to $145 from $111 and keeps a Buy rating on the shares after the company “complemented” its pre-announced Q4 revenue outperformance with an EBITDA and EPS beat and reiterated 2025 revenue growth guidance of 16%-18%. iRhythm “tends to guide conservatively, and we see upside built into these ranges,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm price target raised to $130 from $120 at Oppenheimer
- iRhythm price target raised to $133 from $126 at Baird
- iRhythm price target raised to $135 from $120 at BTIG
- Strong Sales Growth and Strategic Expansion Drive Buy Rating for iRhythm Technologies
- iRhythm price target raised to $104 from $86 at Wells Fargo